Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide
Recent Press Releases
-- Transaction creates strong, diversified rare-disease focused portfolio
-- Novelion Therapeutics completes concurrent financing of approximately $22 million
-- Company to host conference call today at 4:30 p.m. ET
CAMBRIDGE, Mass., Nov. 17, 2016 -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved pricing of JUXTAPID in Japan. The pricing authorization follows Japanese regulatory approval of Juxtapid for the treatment of homozygous familial hypercholesterolemia (HoFH) on September 28, 2016.